# Phase 1: Data Collection & Verification

**Stock:** 6896.HK - Golden Throat Holdings Group Company Limited
**Date:** 2026-02-19
**Status:** âœ… COMPLETED

---

## 1.1 PDF Annual Report Analysis

### Source Documents Analyzed
- 20250425266552.pdf (2024 Annual Report)
- 20240429768942.pdf (2023 Annual Report)
- 20230426011060.pdf (2022 Annual Report)

### Key Findings from Annual Reports

#### Business Overview (2024 Annual Report)
- **Company Description:** Leading throat lozenge manufacturer in China
- **History:** Traces back to 1956 (formerly Liuzhou Candy Factory No. 2)
- **Listing:** Listed on HKEX main board on July 15, 2015
- **Main Product:** é‡‘å—“å­å–‰ç‰‡ (Golden Throat Lozenges) - OTC pharmaceutical

#### 2024 Financial Highlights (from Annual Report)
| Metric | 2024 | 2023 | Change |
|--------|------|------|--------|
| Revenue | RMB 1,185.0M | RMB 961.4M | +23.3% |
| Gross Profit | RMB 894.2M | RMB 697.7M | +28.2% |
| Net Profit | RMB 318.6M | RMB 250.2M | +27.3% |
| EBITDA | RMB 489.1M | RMB 410.8M | +19.1% |
| Proposed Dividend | HK$0.50/share | HK$0.60/share | -16.7% |

#### Strategic Developments (2024)
1. **Brand Recognition:**
   - "éƒ½æ¨‚" (Dule) brand recognized as "China Time-Honored Brand" (ä¸­è¯è€å­—è™Ÿ)
   - Golden Throat Lozenges (OTC) won "Gold Big Product" award
   - Ranked #1 in TCM throat category

2. **Product Innovation:**
   - Sugar-free lozenges for diabetics
   - Probiotic products with patented encapsulation technology
   - Two classic prescriptions in pilot production phase

3. **Capacity Expansion:**
   - Phase 2 R&D base under construction (48 mu site, ~50,000 sqm)
   - Expected to house: PhD workstation, throat/gut/cardio research institutes

#### Risk Factors Identified (from Annual Report)
1. **Foreign Exchange Risk:** Holds HKD and USD deposits, exposed to RMB exchange rate fluctuations
2. **Credit Risk:** Bank lending activities monitored
3. **Liquidity Risk:** Managed through treasury policies
4. **No explicit patent expiration risk disclosed** âš ï¸

### Patent Status - NOT DISCLOSED IN ANNUAL REPORTS

**Important Finding:** The 2024 annual report does NOT explicitly mention:
- Patent expiration dates
- Patent risk factors
- IP protection status
- ä¸­è¯å“ç§ä¿æŠ¤ (TCM Variety Protection) status

This is concerning given the alleged 2026 patent expiration risk.

---

## 1.2 Yahoo Finance Data (Real-Time)

### Basic Information
| Item | Value |
|------|-------|
| Company | Golden Throat Holdings Group Company Limited |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.gxjsz.com |

### Price Data
| Metric | Value |
|--------|-------|
| Current Price | HK$3.18 |
| Previous Close | HK$3.14 |
| 52 Week Low | HK$3.03 |
| 52 Week High | HK$5.65 |
| 50 Day MA | HK$3.16 |
| 200 Day MA | HK$3.86 |
| **Position** | Near 52-week low (trading below 200-day MA) |

### Valuation Metrics
| Metric | Value | Assessment |
|--------|-------|------------|
| Market Cap | HK$2.35B | Small cap |
| Enterprise Value | HK$1.97B | - |
| Trailing P/E | 7.76x | Cheap |
| Price to Book | 1.72x | Reasonable |
| Price to Sales | 2.40x | Reasonable |
| EV/EBITDA | 5.34x | Attractive |

### Dividend Data
| Metric | Value | Assessment |
|--------|-------|------------|
| Dividend Rate | HK$0.50 | - |
| Dividend Yield | 15.72% | Very High |
| Payout Ratio | 125.97% | âš ï¸ Unsustainable! |
| Last Ex-Dividend | 2025-06-16 | - |

**âš ï¸ CRITICAL:** Payout ratio >100% means dividend exceeds earnings - this is UNSUSTAINABLE!

### Profitability
| Metric | Value | Assessment |
|--------|-------|------------|
| Profit Margin | 27.37% | Excellent |
| Operating Margin | 26.11% | Excellent |
| ROE | 21.53% | Excellent |
| ROA | 10.10% | Good |

### Financial Health
| Metric | Value | Assessment |
|--------|-------|------------|
| Total Revenue | HK$979.7M | - |
| Net Income | HK$268.1M | - |
| EBITDA | HK$369.7M | - |
| Total Debt | HK$684M | Moderate |
| Debt to Equity | 56.64% | Elevated |
| Current Ratio | 1.87 | Healthy |
| Quick Ratio | 1.51 | Healthy |
| Total Cash | HK$1,062M | Strong |
| Free Cash Flow | HK$108M | Positive |

### Per Share Data
| Metric | Value |
|--------|-------|
| EPS (TTM) | HK$0.41 |
| Book Value | HK$1.85 |
| Shares Outstanding | 739.3M |
| Float Shares | 223.3M (30.2%) |

### Recent Price History
| Date | Open | High | Low | Close | Volume |
|------|------|------|-----|-------|--------|
| 2026-02-10 | 3.18 | 3.20 | 3.17 | 3.18 | 222,000 |
| 2026-02-11 | 3.18 | 3.18 | 3.16 | 3.18 | 388,500 |
| 2026-02-12 | 3.16 | 3.17 | 3.15 | 3.16 | 422,500 |
| 2026-02-13 | 3.16 | 3.16 | 3.11 | 3.14 | 596,000 |
| 2026-02-16 | 3.18 | 3.18 | 3.18 | 3.18 | 0 |

### Dividend History
| Year | Dividend (HK$) | Notes |
|------|---------------|-------|
| 2017 | 0.12 | - |
| 2018 | 0.12 | - |
| 2019 | 0.12 | - |
| 2020 | 0.12 | - |
| 2021 | 0.06 | Reduced (COVID impact) |
| 2022 | 0.18 | Increasing |
| 2023 | 0.36 | Doubled |
| 2024 | 0.60 | Peak |
| 2025 | 0.50 | Reduced |

---

## 1.3 Peer Comparison Data

### Main Competitors (Throat Lozenges in China)
1. **æ¡‚æ—è¥¿ç“œéœœ** (Guilin Watermelon Frost) - ä¸‰é‡‘åˆ¶è¯
2. **æ…¢ä¸¥èˆ’æŸ ** (Man Yan Shu Ning) - æ¡‚é¾™è¯ä¸š
3. **Strepsils** - Reckitt Benckiser (International)
4. **é‡‘æœå«ç‰‡** - Other local brands

### Market Data (from previous analysis)
- China Throat Lozenge Market Size: USD 296M (2024) â†’ USD 564M (2035)
- Market CAGR: 5.6%
- Golden Throat Market Share: ~25-26%

---

## Key Findings Summary

### âœ… Positive Findings
1. Revenue growth of +23.3% in 2024
2. Strong profit margins (27% net margin)
3. Excellent ROE of 21.5%
4. Healthy cash position (HK$1.06B)
5. Low P/E of 7.76x

### âš ï¸ Concerning Findings
1. **Dividend payout ratio >100%** - UNSUSTAINABLE
2. **Patent risk NOT disclosed** in annual reports - RED FLAG
3. **Debt to equity increased** to 56.6%
4. **Stock trading near 52-week low** - market concerns
5. **Limited public float** (30.2%) - liquidity risk

### ğŸ”´ Critical Issues to Investigate
1. Why is patent risk not disclosed in annual reports?
2. Is the 15.7% dividend yield sustainable with >100% payout?
3. What is the actual patent expiration date?
4. Status of ä¸­è¯å“ç§ä¿æŠ¤ (TCM Variety Protection)?

---

## Next Steps for Phase 2

1. Deep dive into financial statements
2. Calculate owner earnings (Buffett method)
3. Analyze balance sheet quality
4. Assess competitive moat durability
5. Research patent status through alternative sources

---

*Phase 1 Completed: 2026-02-19*
